EOLS

Evolus, Inc.

HealthcareDrug Manufacturers - Specialty & GenericUSUSDPeers →

$6.63

LiveJun 18, 2026

AI Brief

Market cap

$436.62M

52w range

3.86 – 10.20

P / E

—

EPS

—

Volume

1.1M

Revenue · FY

—

Overview Fundamentals Market Narrative & AI

Enterprise value Ratios Multiples Profile

Explain this page

Arphra AIPlain-English read on Evolus, Inc.’s valuation

Business description

· company · SEC profile

Evolus, Inc.

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Founded

—

IPO

Feb 08, 2018

Employees

372

Newport Beach, CA

CEO

David Moatazedi

CFO

—

Exchange

NASDAQ

Fiscal year

—

Identifiers

· company_identifiers

CIK0001570562

CUSIP30052C107

ISINUS30052C1071

FIGIEOLS US

LEI—

Cross-listings

· companies · ISIN

EOLSPrimaryNasdaq Stock MarketusUSD$436.62M
0K16.LLondon Stock ExchangeUSD—

The global universe keeps only the primary listing; the other venues for this security are shown here.